MALVERN, Pa.--(BUSINESS WIRE)--Orthovita, Inc. (NASDAQ:VITA), a leading orthobiologics and biosurgery company, announced today two upcoming presentations related to its VITOSS™ Bone Graft Substitute product. These presentations are based on research conducted independently from Orthovita.
